Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing ahmed glaucoma valve implantation: 2-year follow-up
| Autor: | Vital Paulino Costa, Rafael S. Arcieri, Kleyton A. Barella, Rodrigo Jorge, Jayter Silva Paula, E. S. Arcieri, Danilo J. Secches |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A medicine.medical_specialty Intraocular pressure genetic structures Bevacizumab Anterior Chamber Iris Glaucoma Angiogenesis Inhibitors Neovascular glaucoma Antibodies Monoclonal Humanized Glaucoma valve law.invention Prosthesis Implantation Randomized controlled trial law Ophthalmology Humans Medicine FÁRMACOS Prospective Studies Intravitreal bevacizumab Glaucoma Drainage Implants Intraocular Pressure Rubeosis iridis business.industry General Medicine Middle Aged medicine.disease eye diseases Surgery Glaucoma Neovascular Treatment Outcome Intravitreal Injections Female sense organs business Follow-Up Studies medicine.drug |
| Zdroj: | Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP |
| ISSN: | 1755-375X |
| DOI: | 10.1111/aos.12493 |
| Popis: | Purpose To evaluate the efficacy and safety of intravitreal bevacizumab (IVB) in eyes with neovascular glaucoma (NVG) undergoing Ahmed glaucoma valve (AGV) implantation. Methods This was a multicentre, prospective, randomized clinical trial that enrolled 40 patients with uncontrolled neovascular glaucoma that had undergone panretinal photocoagulation and required glaucoma drainage device implantation. Patients were randomized to receive IVB (1.25 mg) or not during Ahmed valve implant surgery. Injections were administered intra-operatively, and 4 and 8 weeks after surgery. Results After a mean follow-up of 2.25 ± 0.67 years (range 1.5–3 years), both groups showed a significant decrease in IOP (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text